한글목차

경피 패치 시장은 2023-20281년에 20억 달러, 예측 기간 중 CAGR은 5.65%로 성장할 것으로 예측됩니다.

경피 패치 시장의 전체적인 분석, 시장 규모·예측, 동향, 성장 촉진요인, 과제, 약 25개 벤더를 다룬 벤더 분석 등을 제공합니다.

현재의 시장 시나리오, 최신 동향과 촉진요인, 시장 환경 전체에 관한 최신 분석을 제공하고 있습니다. 시장은 비침습적 약물전달 방법에 대한 수요의 증가, 만성질환의 유병률 증가, 경피 패치 개발에 대한 투자 증가에 의한 헬스케어 지출의 증가에 의해 촉진되고 있습니다.

본 조사에서는 향후 수년간 경피 패치 시장 성장을 촉진하는 주요 요인의 하나로 약물전달 효율 향상을 위한 마이크로니들 패치의 개발을 들고 있습니다. 또한 경피 패치의 피부과학 분야 및 화장품 분야에 대한 응용 확대, 패치 제조에서 지속가능한 생분해성 재료의 채택은 시장의 큰 수요로 연결됩니다.

목차

제1장 주요 요약

• 시장 개요

제2장 시장 구도

• 시장 에코시스템

제3장 시장 규모의 평가

• 시장의 정의
• 시장 부문 분석
• 시장 규모 2023
• 시장 전망 2023-2028

제4장 시장 규모 실적

• 세계의 경피 패치 시장 2018-2022
• 용도별 부문 분석 2018-2022
• 최종사용자 부문 분석 2018-2022
• 지역별 부문 분석 2018-2022

제5장 Five forces 분석

• Five Forces 요약
• 구매자의 교섭력
• 공급 기업의 교섭력
• 신규 진출업체의 위협
• 대체품의 위협
• 경쟁의 위협
• 시장 현황

제6장 시장 세분화 : 용도별

• 시장 부문
• 비교 : 용도별
• 통증 관리 : 시장 규모와 예측 2023-2028
• 중추신경계 장애 : 시장 규모와 예측 2023-2028
• 호르몬 투여 : 시장 규모와 예측 2023-2028
• 심혈관질환 : 시장 규모와 예측 2023-2028
• 기타 : 시장 규모와 예측 2023-2028
• 시장 기회 : 용도별

제7장 시장 세분화 : 최종사용자별

• 시장 부문
• 비교 : 최종사용자별
• 홈케어 : 시장 규모와 예측 2023-2028
• 병원과 진료소 : 시장 규모와 예측 2023-2028
• 시장 기회 : 최종사용자별

제8장 고객 상황

• 고객 상황의 개요

제9장 지역별 상황

• 지역별 세분화
• 지역별 비교
• 북미 : 시장 규모와 예측 2023-2028
• 유럽 : 시장 규모와 예측 2023-2028
• 아시아 : 시장 규모와 예측 2023-2028
• 세계의 기타 지역 : 시장 규모와 예측 2023-2028
• 미국 : 시장 규모와 예측 2023-2028
• 중국 : 시장 규모와 예측 2023-2028
• 독일 : 시장 규모와 예측 2023-2028
• 영국 : 시장 규모와 예측 2023-2028
• 일본 : 시장 규모와 예측 2023-2028
• 시장 기회 : 지역별

제10장 촉진요인, 과제 및 동향

• 시장 촉진요인
• 시장이 해결해야 할 과제
• 촉진요인과 과제의 영향
• 시장 동향

제11장 벤더 구도

• 개요
• 벤더 구도
• 혼란의 상황
• 업계의 리스크

제12장 벤더 분석

• 대상 벤더
• 벤더의 시장 포지셔닝
• Agile Therapeutics Inc.
• Alvogen Iceland ehf
• Bayer AG
• Boehringer Ingelheim International GmbH
• Endo International Plc
• Hisamitsu Pharmaceutical Co. Inc.
• IontoPatch
• Johnson and Johnson Services Inc.
• Lead Chemical Co. Ltd.
• Luye Pharma Group Ltd.
• Nitto Denko Corp.
• Novartis AG
• Purdue Pharma LP
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

제13장 부록

영문목차

The transdermal patches market is forecasted to grow by USD 2.00 bn during 2023-2028, accelerating at a CAGR of 5.65% during the forecast period. The report on the transdermal patches market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing demand for non-invasive drug delivery methods, increasing prevalence of chronic diseases, and rising healthcare expenditure owing to increasing investment in transdermal patch development.

Technavio's transdermal patches market is segmented as below:

By Application

• Pain management
• Central nervous system disorders
• Hormonal application
• Cardiovascular diseases
• Others

By End-user

• Homecare
• Hospitals and clinics

By Geography

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the development of microneedle patches for enhanced drug delivery efficiency as one of the prime reasons driving the transdermal patches market growth during the next few years. Also, the expansion of transdermal patch applications into dermatological and cosmetic fields and the adoption of sustainable and biodegradable materials in patch manufacturing will lead to sizable demand in the market.

The report on the transdermal patches market covers the following areas:

• Transdermal patches market sizing
• Transdermal patches market forecast
• Transdermal patches market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading transdermal patches market vendors that include Alvogen Iceland ehf, Boehringer Ingelheim International GmbH, Endo International Plc, Hisamitsu Pharmaceutical Co. Inc., IontoPatch, Johnson and Johnson Services Inc., Lead Chemical Co. Ltd., Luye Pharma Group Ltd., Medherant Ltd., Mundipharma International Ltd., Nitto Denko Corp., Novartis AG, Purdue Pharma LP, Sparsha Pharma International Pvt. Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., AdhexPharma SAS, Agile Therapeutics Inc., Bayer AG, and Evernow Inc. Also, the transdermal patches market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview

2 Market Landscape

• 2.1 Market ecosystem

3 Market Sizing

• 3.1 Market definition
• 3.2 Market segment analysis
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028

4 Historic Market Size

• 4.1 Global transdermal patches market 2018 - 2022
• 4.2 Application Segment Analysis 2018 - 2022
• 4.3 End User Segment Analysis 2018 - 2022
• 4.4 Geography Segment Analysis 2018 - 2022

5 Five Forces Analysis

• 5.1 Five forces summary
• 5.2 Bargaining power of buyers
• 5.3 Bargaining power of suppliers
• 5.4 Threat of new entrants
• 5.5 Threat of substitutes
• 5.6 Threat of rivalry
• 5.7 Market condition

6 Market Segmentation by Application

• 6.1 Market segments
• 6.2 Comparison by Application
• 6.3 Pain management - Market size and forecast 2023-2028
• 6.4 Central nervous system disorders - Market size and forecast 2023-2028
• 6.5 Hormonal application - Market size and forecast 2023-2028
• 6.6 Cardiovascular diseases - Market size and forecast 2023-2028
• 6.7 Others - Market size and forecast 2023-2028
• 6.8 Market opportunity by Application

7 Market Segmentation by End-user

• 7.1 Market segments
• 7.2 Comparison by End-user
• 7.3 Homecare - Market size and forecast 2023-2028
• 7.4 Hospitals and clinics - Market size and forecast 2023-2028
• 7.5 Market opportunity by End-user

8 Customer Landscape

• 8.1 Customer landscape overview

9 Geographic Landscape

• 9.1 Geographic segmentation
• 9.2 Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• 9.4 Europe - Market size and forecast 2023-2028
• 9.5 Asia - Market size and forecast 2023-2028
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• 9.7 US - Market size and forecast 2023-2028
• 9.8 China - Market size and forecast 2023-2028
• 9.9 Germany - Market size and forecast 2023-2028
• 9.10 UK - Market size and forecast 2023-2028
• 9.11 Japan - Market size and forecast 2023-2028
• 9.12 Market opportunity by geography

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• 11.3 Landscape disruption
• 11.4 Industry risks

12 Vendor Analysis

• 12.1 Vendors covered
• 12.2 Market positioning of vendors
• 12.3 Agile Therapeutics Inc.
• 12.4 Alvogen Iceland ehf
• 12.5 Bayer AG
• 12.6 Boehringer Ingelheim International GmbH
• 12.7 Endo International Plc
• 12.8 Hisamitsu Pharmaceutical Co. Inc.
• 12.9 IontoPatch
• 12.10 Johnson and Johnson Services Inc.
• 12.11 Lead Chemical Co. Ltd.
• 12.12 Luye Pharma Group Ltd.
• 12.13 Nitto Denko Corp.
• 12.14 Novartis AG
• 12.15 Purdue Pharma LP
• 12.16 Teva Pharmaceutical Industries Ltd.
• 12.17 Viatris Inc.

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• 13.3 Currency conversion rates for US$
• 13.4 Research methodology
• 13.5 List of abbreviations